Literature DB >> 15754268

Application of GFR-estimating equations in Chinese patients with chronic kidney disease.

Li Zuo1, Ying-Chun Ma, Yu-Hong Zhou, Mei Wang, Guo-Bin Xu, Hai-Yan Wang.   

Abstract

BACKGROUND: To evaluate whether the Modification of Diet in Renal Disease (MDRD) equations could be applied accurately to Chinese patients with chronic kidney disease (CKD), glomerular filtration rates (GFRs) estimated by using MDRD equation 7 (7GFR), the abbreviated MDRD equation (aGFR), and the Cockcroft-Gault equation (cGFR) were compared in patients with different stages of CKD.
METHODS: The study enrolled patients with CKD diagnosed according to the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative guidelines. All patients were older than 18 years and without acute renal function deterioration, edema, skeletal muscle atrophy, or amputation. Sex, age, body height, and body weight were recorded, and plasma creatinine levels were measured by means of Jaffe's kinetic method using a Hitachi 7600 analyzer (Hitachi, Tokyo, Japan; reagents from Roche Diagnostics, Mannheim, Germany). Creatinine, urea, and albumin were measured in a single clinical laboratory. Dual plasma sampling of technetium Tc 99m-labeled diethylene triamine pentaacetic acid plasma clearance was used as the reference standard GFR (sGFR) for comparison of 7GFRs, aGFRs, and cGFRs at different stages of CKD.
RESULTS: The study enrolled 261 patients, including 146 men and 115 women. Causes of CKD included primary or secondary glomerular disease, obstructive kidney disease, chronic tubulointerstitial disease, and others. Values for 7GFR, aGFR, and cGFR were significantly greater than for sGFR in patients with CKD stages 4 to 5 (the lower the sGFR, the greater the difference); whereas 7GFR, aGFR, and cGFR were significantly lower than sGFR in patients with CKD stage 1.
CONCLUSION: Our results show that in a Chinese population with CKD, MDRD equation 7 and the abbreviated MDRD equation overestimated GFR in patients with CKD stages 4 to 5 and underestimated GFR in those with CKD stage 1. These results indicate that careful modification of these equations may be necessary in Chinese populations with CKD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754268     DOI: 10.1053/j.ajkd.2004.11.012

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  55 in total

1.  The relationship of cystatin C, creatinine, estimated GFR, and cardiovascular events.

Authors:  Luo Zhang; Li Ni; Jiagao Lv
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

2.  The Chronic Kidney Disease Epidemiology Collaboration equation improves the detection of hyperfiltration in Chinese diabetic patients.

Authors:  Fangya Zhao; Lei Zhang; Junxi Lu; Kaifeng Guo; Mian Wu; Haoyong Yu; Mingliang Zhang; Yuqian Bao; Haibing Chen; Weiping Jia
Journal:  Int J Clin Exp Med       Date:  2015-12-15

3.  End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry.

Authors:  X L Yang; W Y So; A P S Kong; P Clarke; C S Ho; C W K Lam; M H L Ng; R R Lyu; D D Yin; C C Chow; C S Cockram; P C Y Tong; J C N Chan
Journal:  Diabetologia       Date:  2006-08-30       Impact factor: 10.122

Review 4.  How to measure renal function in clinical practice.

Authors:  Jamie Traynor; Robert Mactier; Colin C Geddes; Jonathan G Fox
Journal:  BMJ       Date:  2006-10-07

5.  Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease.

Authors:  Enyu Imai; Masaru Horio; Kosaku Nitta; Kunihiro Yamagata; Kunitoshi Iseki; Shigeko Hara; Nobuyuki Ura; Yutaka Kiyohara; Hideki Hirakata; Tsuyoshi Watanabe; Toshiki Moriyama; Yasuhiro Ando; Daiki Inaguma; Ichiei Narita; Hiroyasu Iso; Kenji Wakai; Yoshinari Yasuda; Yusuke Tsukamoto; Sadayoshi Ito; Hirofumi Makino; Akira Hishida; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

6.  Report of the Asian Forum of Chronic Kidney Disease Initiative (AFCKDI) 2007. "Current status and perspective of CKD in Asia": diversity and specificity among Asian countries.

Authors:  Yusuke Tsukamoto; HaiYan Wang; Gavin Becker; Hung-Chun Chen; Dae-Suk Han; David Harris; Enyu Imai; Vivekanand Jha; Philip K T Li; Evan J C Lee; Seiichi Matsuo; Yasuhiko Tomino; Kriang Tungsanga; Kunihiro Yamagata; Akira Hishida
Journal:  Clin Exp Nephrol       Date:  2009-03-14       Impact factor: 2.801

7.  Socioeconomic disadvantage and kidney disease in the United States, Australia, and Thailand.

Authors:  Sarah L White; Kevin McGeechan; Michael Jones; Alan Cass; Steven J Chadban; Kevan R Polkinghorne; Vlado Perkovic; Paul J Roderick
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

8.  A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease.

Authors:  Dawei Xie; Marshall M Joffe; Steven M Brunelli; Gerald Beck; Glenn M Chertow; Jeffrey C Fink; Tom Greene; Chi-yuan Hsu; John W Kusek; Richard Landis; James Lash; Andrew S Levey; Andrew O'Conner; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Hao Wang; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

9.  Geographic difference in the prevalence of chronic kidney disease among Japanese screened subjects: Ibaraki versus Okinawa.

Authors:  Kunitoshi Iseki; Masaru Horio; Enyu Imai; Seiichi Matsuo; Kunihiro Yamagata
Journal:  Clin Exp Nephrol       Date:  2008-10-15       Impact factor: 2.801

10.  Study Protocol--accurate assessment of kidney function in Indigenous Australians: aims and methods of the eGFR study.

Authors:  Louise J Maple-Brown; Paul D Lawton; Jaquelyne T Hughes; Suresh K Sharma; Graham Rd Jones; Andrew G Ellis; Wendy Hoy; Alan Cass; Richard J Macisaac; Ashim K Sinha; Mark Ab Thomas; Leonard S Piers; Leigh C Ward; Katrina Drabsch; Sianna Panagiotopoulos; Robyn McDermott; Kevin Warr; Sajiv Cherian; Alex Brown; George Jerums; Kerin O'Dea
Journal:  BMC Public Health       Date:  2010-02-19       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.